Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Liabilities (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Total Liabilities for 16 consecutive years, with $675.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 14.32% year-over-year to $675.6 million, compared with a TTM value of $675.6 million through Dec 2025, up 14.32%, and an annual FY2025 reading of $675.6 million, up 14.32% over the prior year.
  • Total Liabilities was $675.6 million for Q4 2025 at Amicus Therapeutics, up from $638.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $675.6 million in Q4 2025 and bottomed at $559.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $607.3 million, with a median of $604.4 million recorded in 2022.
  • The sharpest move saw Total Liabilities surged 68.28% in 2021, then fell 4.33% in 2024.
  • Year by year, Total Liabilities stood at $597.8 million in 2021, then increased by 0.56% to $601.1 million in 2022, then grew by 2.76% to $617.7 million in 2023, then decreased by 4.33% to $591.0 million in 2024, then rose by 14.32% to $675.6 million in 2025.
  • Business Quant data shows Total Liabilities for FOLD at $675.6 million in Q4 2025, $638.4 million in Q3 2025, and $611.0 million in Q2 2025.